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There remains an urgent need for a prophylactic HIV vaccine. We compared combined 
MVA and adjuvanted gp140 to sequential MVA/gp140 after DNA priming. We expected 
Env-specific CD4+ T-cells after DNA and MVA priming, and Env-binding antibodies in 
100% individuals after boosting with gp140 and that combined vaccines would not 
compromise safety and might augment immunogenicity. Forty volunteers were primed 
three times with DNA plasmids encoding (CN54) env and (ZM96) gag-pol-nef at 0, 4 
and 8 weeks then boosted with MVA-C (CN54 env and gag-pol-nef) and glucopyranosyl 
lipid adjuvant—aqueous formulation (GLA-AF) adjuvanted CN54gp140. They were 
randomised to receive them in combination at the same visit at 16 and 20 weeks (accel-
erated) or sequentially with MVA-C at 16, 20, and GLA-AF/gp140 at 24 and 28 weeks 
(standard). All vaccinations were intramuscular. Primary outcomes included ≥grade 
3 safety events and the titer of CN54gp140-specific binding IgG. Other outcomes 
included neutralization, binding antibody specificity and T-cell responses. Two partici-
pants experienced asymptomatic ≥grade 3 transaminitis leading to discontinuation of 
vaccinations, and three had grade 3 solicited local or systemic reactions. A total of 
100% made anti-CN54gp140 IgG and combining vaccines did not significantly alter the 
response; geometric mean titer 6424 (accelerated) and 6578 (standard); neutralization 
of MW965.2 Tier 1 pseudovirus was superior in the standard group (82 versus 45% 
responders, p =  0.04). T-cell ELISpot responses were CD4+ and Env-dominant; 85 
and 82% responding in the accelerated and standard groups, respectively. Vaccine-
induced IgG responses targeted multiple regions within gp120 with the V3 region most 
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inTrODUcTiOn
In an era of antiretroviral medication for the treatment and pre-
vention of HIV, concerns around access, toxicity, and escalating 
cost suggest that a vaccine for HIV is still likely to be the most 
effective and sustainable way of reducing new infections (1, 2). 
Of the five HIV efficacy vaccine trials to date, there has only been 
only one to demonstrate significant, if modest efficacy; the RV144 
“Thai” trial (3–8). This study with 16,402 subjects randomized 
to four immunizations with ALVAC given twice and then twice 
more with AIDSVAX B/E adjuvanted with ALUM, reported 31.2% 
protection (95% CI 1–51) against acquisition, without impacting 
HIV viral load or CD4+ T cell count (8). Subsequent immuno-
logical analyzes reported an inverse correlation between the levels 
of circulating polyclonal non-neutralizing antibodies and risk of 
infection, which has been associated with Fc receptor-mediated 
antibody effector functions (9–15). The results stimulated interest 
in prime-boost pox and protein combination vaccine approaches 
and the role of non-neutralizing antibodies.
Heterologous prime boost regimens employing DNA, viral 
vectors, and/or recombinant proteins have generated robust cel-
lular and humoral responses maximizing breadth and potency 
while limiting the attenuating effects of vector specific immunity 
(16–20). DNA vaccines have been shown to prime cellular and 
humoral immune responses, upon boosting with recombinant 
vectors (21). The EuroVacc trials demonstrated that DNA prime, 
NYVAC boost increased the frequency, magnitude, and breadth 
of HIV-specific T-cell ELISpot responses (22, 23) and that three 
DNA priming immunizations were more immunogenic than 
two (24). A recent clinical trial comparing different prime boost 
regimens showed no benefit of DNA priming for Env-specific 
antibody responses but evidence of an improvement in T-cell 
responses, although overall immunogenicity was lower than seen 
previously in response to the same DNA and MVA vaccines (25).
In this study, the UK HIV Vaccine Consortium built upon 
these prior data showing enhanced immunogenicity of DNA 
prime, pox vector boost, and the protection seen in RV144 by 
protein boosting, to produce homologous DNA, MVA, and 
gp140 immunogens. We have made DNA plasmids and an MVA 
expressing matched HIV-1 subtype C (CN54)-derived inserts, 
and adjuvanted trimeric glycoprotein with a view for use in 
Sub-Saharan Africa. We believe this strategy is ideally suited to 
inducing Env-dominant CD4+ T-cell responses, favoring the 
development of high titer Env-specific antibody responses. The 
same trimeric recombinant CN54gp140 protein has already been 
administered to 469 individuals in a variety of trial settings (with 
and without DNA priming, or adjuvant and via different routes), 
showing excellent safety and induction of vaccine specific anti-
bodies (26–28). When given systemically with glucopyranosyl 
lipid adjuvant—aqueous formulation (GLA-AF) after priming 
with heterologous DNA and MVA, high titer systemic binding 
antibodies were seen to the protein (28).
Prompted by the results of the RV144 trial, but with long-term 
feasibility in mind, we have explicitly assessed the impact of 
combining pox (MVA-C) and GLA-AF adjuvanted CN54gp140 
protein after priming with DNA. We compared the safety and 
immunogenicity of two regimens using identical vaccines; given 
sequentially in one regimen (standard) and with the pox and 
protein combined in the other (accelerated). We shortened the 
regimens relative to our previous studies and RV144 by reducing 
the intervals between vaccinations, with 4 weeks between each 
of three DNA immunizations, 8 weeks between prime and first 
boost, and 4 weeks between subsequent boosts. We administered 
vaccinations intramuscularly (IM) for logistical ease and with a 
view to eventual roll out in resource limited settings.
The DNA and MVA-C were produced by UK HVC and based 
closely on those used previously (EV02 Eudract 2004-001802-28 
and EV03 Eudract 2006-006141-13), with matched CN54/ZM96 
subtype C-derived gag pol nef and env inserts. We anticipated 
Env-dominated CD4+ T-cell responses and modest Env-specific 
antibody responses after DNA and MVA, with the development 
of high titer binding and neutralizing antibody responses after 
boosting with adjuvanted CN54gp140 protein (29–31). Based 
on our previous studies, we expected that the immunogens 
would prove more potent B-cell immunogens than the ALVAC/
AIDSVAX/ALUM used in RV144 and that the combined MVA/
CN54p140/GLA might augment immunogenicity, offering the 
potential for a short regimen.
MaTerials anD MeThODs
study Design and conduct
This was a Phase I randomized open-label trial conducted at 
two UK centers: Imperial College London and Surrey Clinical 
Research Centre. Participants were recruited through advertising, 
immunodominant and no differences between groups detected. Combining MVA and 
gp140 vaccines did not result in increased adverse events and did not significantly 
impact upon the titer of Env-specific binding antibodies, which were seen in 100% indi-
viduals. The approach did however affect other immune responses; neutralizing antibody 
responses, seen only to Tier 1 pseudoviruses, were poorer when the vaccines were 
combined and while T-cell responses were seen in >80% individuals in both groups and 
similarly CD4 and Env dominant, their breadth/polyfunctionality tended to be lower when 
the vaccines were combined, suggesting attenuation of immunogenicity and cautioning 
against this accelerated regimen.
Keywords: hiV vaccine, phase i trial, Dna, MVa, envelope protein
FigUre 1 | Trial flow.
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social media, and a dedicated website. The study documents were 
reviewed and approved by the NRES London—West London and 
GTAC Ethics Committee (13/LO/0115), and the UK Medicines 
and Healthcare products Regulatory Agency, and all participants 
gave fully informed written consent according to the Declaration 
of Helsinki before any study procedures were conducted. The 
trial was registered with the European Union Drug Regulating 
Authorities for Clinical Trials (EUDRACT TC 2012-003277-26) 
and Clinical Trials.gov (NCT01922284) and with the UK Clinical 
Trials Research Network (UKRN-14173). Laboratory personnel 
were blind to the allocation. Participants were block randomized 
centrally using a computer generated algorithm with a back-up 
manual procedure, and the randomization list was stratified by 
center and gender.
The primary objective was to compare the safety and immu-
nogenicity of two vaccination regimens, one of which was 
shortened by 8  weeks (Figure  1) in healthy HIV-uninfected 
male and female volunteers aged 18–45 years at low risk of HIV 
infection. The primary outcomes were (i) a severe (grade  3) 
or worse local or systemic clinical or laboratory adverse event 
or an event that led to a clinical decision to discontinue vac-
cinations and (ii) the magnitude of the CN54gp140-specific 
IgG antibody response in serum 4  weeks after the final 
immunization. Secondary outcomes of interest included IFNγ 
T-cell ELISpot, intracellular cytokine, neutralizing antibody, 
CN54gp140-specific serum IgA, mucosal IgG, and IgA anti-
body responses.
safety evaluations
Local and systemic events recognized to be associated with 
licensed vaccines were solicited systematically at clinical cent-
ers prior to, 10 min and 1 h after each vaccination, and then 
7 days later, and by diary card. Clinical and laboratory events 
were collected via an open question at each visit and through 
routine hematology and chemical pathology performed at 
screening, 1 week after each vaccination and at week 40 in both 
groups.
Table 1 | schedule of doses, formulation, and routes of immunization.
group route of immunization; dose of vaccine
Weeks 0, 4, 8 Weeks 16, 20 Weeks 24, 28
1 (n = 20) 4 mg DNA (CN54) in 
1 ml (right arm)
1 × 108 TCID50 
MVA-C in 0.5 ml 
(left arm) + [100 µg 
CN54gp140 + 5 µg 
glucopyranosyl lipid 
adjuvant—aqueous 
formulation (GLA-AF)] 
in 0.4 ml (right arm)
Nothing
4 mg DNA (ZM96) in 
1 ml (left arm)
Intramuscular (IM) IM
2 (n = 20) 4 mg DNA (CN54) in 
1 ml (right arm)
1 × 108 TCID50 MVA-C 
in 0.5 ml (left arm)
(100 µg 
CN54gp140 + 5 µg 
GLA-AF) in 0.4 ml 
(right arm)
4 mg DNA (ZM96) in 
1 ml (left arm)
IM IM IM
4
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immunological specimens
Blood was taken for immunological assessments at weeks 0, 4, 8, 
16, 20, and 24 and 40 for all participants and at weeks 28 and 32 
for those in the standard group. Mucosal samples were collected 
at weeks 0 and 24 for the accelerated and at weeks 0 and 32 for the 
standard group. Peripheral blood mononuclear cells (PBMCs) 
were isolated using density gradient separation, frozen in a mix-
ture of fetal bovine serum (Sigma-Aldrich, St. Louis, MO, USA) 
and DMSO (9:1 ratio) using a Kryo 560-16 rate controlled freezer 
(Planer, Sunbury-On-Thames, UK). PBMCs were shipped and 
stored in vapor phase liquid nitrogen as previously (32). Genital 
tract secretions from women were collected using the Instead 
Softcup™ (Evofem Inc.) and urethral swabs (Hunt Biologics, 
UK) from male volunteers and rectal Floq™ swabs were taken 
when possible from males and females, primarily to assess the 
feasibility of the sampling method. Vaginal samples were col-
lected, processed, and analyzed as described previously (33). 
Urethral swabs were collected from male participants in clinic by 
inserting the swab and allowing it to absorb mucosal secretions 
for 2 min. Rectal Floq™ swabs were inserted into the anus and 
rotated to collect secretions. Rectal and urethral swabs were either 
snap frozen on receipt or processed directly. Processing involved 
addition of 300 µl of extraction buffer [250 mM NaCl, 1× protease 
inhibitor cocktail set 1 (Calbiochem) in phosphate buffered saline 
(1× DPBS)] to the swabs, vortexing for 1 min and placing on ice 
to 15 min. Rectal and urethral swabs were then placed in the top 
chamber of a spin X tube, centrifuged at max speed (10,000 g) for 
2 min and the eluates either analyzed immediately or aliquoted 
and frozen at −80°C until analysis.
Vaccines and schedule
The recombinant clade C HIV-1 envelope gp140 protein 
(CN54gp140) is a naturally cleavage resistant envelope clone of 
97CN54 (34). The protein was manufactured to GMP specifica-
tion (33) (Polymun Scientific Austria) generating a product which 
was >80% trimeric protein with a projected mass of 420 kD and 
a defined glycan (35). A total of 100 µg CN54gp140 was mixed 
with 5 μg GLA-AF (IDRI, Seattle, WA, USA) and administered 
in a volume of 0.4 ml as below. There were two DNA plasmids; 
one encoded (CN54) env and the other a (ZM96) gag-pol-nef 
fusion protein. Both open-reading frames were RNA and codon 
optimized (GeneArt AG, Regensburg, Germany). Both plasmids 
utilized a chimeric CMV enhancer/promoter with a human 
T-cell leukemia type 1 regulatory element to drive expression 
(36). The MVA-C (Mariano Esteban CSIC, Spain) expressed the 
CN54gp120 Env and Gag-Pol-Nef polyprotein from two back-to-
back synthetic early/late transcriptional promoters (37, 38). All 
vaccinations were given IM into the deltoid muscles of the upper 
arms. 4 mg of each DNA plasmid was given to all participants at 
weeks 0, 4, and 8 in a volume of 1.0 ml (8.0 mg in total) with the 
same plasmid given into the same arm on each occasion (CN54 
plasmid into right arm and ZM96 into left arm). In the “standard” 
group, 108  TCID50 MVA-C was given at weeks 16 and 20 in a 
volume of 1.0  ml (into left arm) and then 100  µg CN54gp140 
mixed with 5 µg GLA-AF at weeks 24 and 28 in a volume of 0.4 ml 
(into right arm). In the “accelerated” group, 108  TCID50 MVA-C 
in 1.0 ml was given at the same time as 100 µg CN54gp140 mixed 
with 5 µg GLA-AF at weeks 16 and 20 in 0.4 ml IM as above (with 
MVA-C into left and CN54gp140/GLA-AF into the right arms as 
shown, see Table 1).
humoral assays
CN54gp140-Specific Antibody ELISA
Serum and mucosal binding antibodies against recombinant 
CN54gp140 were measured using a standardized ELISA with 
minor modifications. 96-well ELISA plates were coated with 
50 µl per well of capture antigen CN54gp140 (1 µg/ml) (Polymun, 
Austria). Human standards (IgG or IgA) were captured by coat-
ing wells with a combination of α-Human κ and α-Human λ 
(1:1 ratio) capture antibodies. After incubation at 37°C for 1 h, 
plates were washed with PBST then blocked for 1  h at 37°C 
with 200 µl/well of assay buffer (PBS + 1% BSA) then washed, 
as above (26). Standards were prepared by adding the required 
concentration of either human IgG or IgA. Serum samples were 
screened at 1:100 dilution, Softcup cervical mucosal samples at 
1:10 dilution. Samples, standards, and controls (normal human 
sera) were added to triplicate wells. Detection antibodies were 
added following incubation and washing, either goat α-Human 
IgG-HRP or goat α-Human IgA-HRP detection antibodies. 
After incubation and washing, plates were developed by the 
addition of TMB substrate (KPL) followed by addition of 50 µl 
of Stop Solution (KPL). Absorbencies were read immediately 
at 450 nm using a VersaMax plate-reader (Molecular Devices). 
A response detected for both IgG and IgA was defined as OD 
A450  nm value >0.2; samples below this value were deemed 
negative or response not detected. Samples were further diluted 
following screening assays if positive with a series of dilutions 
in order to extrapolate a concentration expressed as microgram 
per milliliter of specific IgG or IgA using the ELISA software 
SoftMax Pro v 5.4. Serum samples that were positive by the 
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above method were also tested in a conventional endpoint titer 
assay as previously described (32).
Neutralizing Antibody Responses
Neutralizing antibody responses against a panel of Tier 1 
(MW965.26, MN.3, 00836-2.5, ZM197M-PB7) and Tier 2 
(Ce1176_A3, Ce703010217_B6, HIV-2510-2) pseudo viruses 
were measured using TZM-bl cells in the lab of David Montefiori 
as described previously (27, 39). Briefly, pseudoviruses (TZM-bl 
assay) were incubated with serial dilutions of sera and added to 
their respective target cells. Luciferase expression was measured 
after 2 days (TZM-bl), and IC50s were determined as the serum 
concentration that reduced the background-subtracted relative 
light units by 50% compared to virus-only control wells.
cellular assays
IFNγ ELISpot
Cellular immunogenicity was assessed by standardized IFNγ 
ELISpot assay using frozen PBMCs as previously described (32, 
39). One day prior to assay setup, PBMCs were thawed in and rested 
overnight in RPMI medium containing 20% heat-inactivated 
fetal calf serum (HIFCS), glutamine, penicillin, and streptomycin 
(R20) (all supplied by Sigma, Poole, UK) at 37°C, 5% CO2. 96-well 
PVDF membrane (MSIPS4510 Millipore, UK) plates were coated 
with mouse anti-human IFNγ (10μg/ml; MabTech clone 1-D1K) 
in sterile PBS. On the day of assay setup, coated ELISpot plates 
were washed with sterile PBS and blocked with RPMI 10% HIFCS 
(R10) for at least 1 h. Synthetic peptides (15-mers overlapping by 
11aa; HPLC purified >90%, JPT Germany) covering the HIV-1 
gene inserts and CMV pp65 gene were dissolved and pooled in 
dimethyl sulfoxide (DMSO, Sigma), further diluted in PBS and 
R10 to achieve a final assay concentration of 1.5 µg/ml per peptide 
and 0.45% v/v DMSO. 100  µl volumes of HIV-1 peptide pools 
were added to ELISpot plate wells in quadruplicate. The CMV 
pp65 peptide pool and phytohemagglutinin (PHA, 10  µg/ml) 
were plated as positive controls in duplicate wells for each. For a 
negative control, quadruplicate wells containing a mock stimulus 
(0.45% v/v DMSO final concentration in R10) were used. Rested 
PBMCs were recovered and washed in R10 and viable cells counted 
using a Beckman Coulter Vi-Cell counter. A total of 200,000 viable 
PBMCs (in 50 µl) were added to all wells except for 1 well with 
R10 only (reagent control well). Plates were incubated at 37°C, 5% 
CO2 overnight (16–24 h). All subsequent steps were performed at 
room temperature. Plates were washed six times with PBS/0.05% 
v/v Tween 20 (Sigma) and the production of IFNγ by T-cells was 
assessed by addition of 1 μg/ml biotinylated mouse-anti-human 
IFNγ antibody (clone 7-B6-1, Mabtech, Sweden) for 2–4 h. Plates 
were washed as before and ABC peroxidase–avidin–biotin com-
plex (PK6100, Vector labs, UK) was added for 1 h, followed by 
three washes with PBS/Tween and three washes with PBS. Spots 
were developed with addition of filtered AEC/H2O2 substrate 
solution (Sigma) for 4 min. The reaction was stopped by wash-
ing plates under running tap water, plate underdrains removed, 
and plates allowed to dry overnight in the dark before spots in 
each well were counted using an automated AID ELISpot reader 
(AutoImmun Diagnostika, Germany).
A positive response was defined by the following criteria: 
(1) average number of background-subtracted spots in a single 
pool >specified cutoff of 38 SFC/106 PBMCs (40). The cutoffs 
were derived from assessing peptide pool responses in PBMCs 
from 178 HIV-1 seronegative individuals; (2) for each pool, 
if the number of replicates was 2 or ≥3, then the coefficient of 
variation (standard deviation/mean) between replicates had to be 
≤50% or ≤70%, respectively; (3) mean count had to be >4 times 
mean background; (4) mean background had to be ≤55 SFC/106 
PBMCs. Samples with mean background >55 SFC/106 PBMCs 
were considered failures, were repeated, and excluded from all 
analyses if failed a second time. The breadth of responses was 
described in terms of the number of individual peptide pools to 
which each individual responded.
Flow cytometry
Antigen-specific cytokine secretion was assessed using a vali-
dated seven-color polychromatic flow cytometry panel assessed 
at the IAVI human immunology lab in London. Previously 
frozen PBMCs were coincubated with peptide pools matched 
to the inserts at 1.5  µg/ml (as previously described), 1  µg/ml 
SEB (Sigma-Aldrich, St. Louis, MO, USA), or mock stimuli and 
Brefeldin A (Sigma-Aldrich, Poole Dorset, UK) for 6 h at 37°C. 
Cells were stained for viability with LIVE/DEAD Fixable Violet 
Dead Cell Stain Kit (Invitrogen, Eugene, OR, USA), fixed and then 
stained intracellularly using anti-CD4 PeCF594 (clone RPA-T4), 
anti-CD8 BV421 (RPA-T8), anti-CD3 APC-H7 (SK7), anti-IFNγ 
APC (B27), anti-IL2-PE (MQ1-17HI2), and anti-TNFα-FITC 
(Mab11) (all Becton Dickinson, San Jose, CA, USA). Cells were 
washed and acquired on the same day. At least 5,000 CD8 and 
CD4+ CD3+ viable, singlet lymphocyte events were acquired 
using BD Fortessa II instruments. Data were analyzed and pre-
sented using FlowJo (version 9.8 Treestar, Ashland, OR, USA). 
Samples were failed where fewer than 5,000 events in the prede-
fined populations were acquired or where mock IFNγ responses 
were above 0.2% of either parental population. Flow cytometric 
analysis was performed at baseline, and 16 and 24 weeks for group 
1, and additionally at 32 weeks for group 2.
Peptide array Mapping
The microarrays were processed according to the manufacturers 
instructions with minor modifications (www.jpt.com). Briefly, 
the slides were pre-incubated with T20 blocking buffer (Thermo 
Fisher) for 10 min. Plasma samples were then added at a dilu-
tion of 1:100 in T20 blocking buffer and incubated for 2  h at 
room temperature with gentle shaking before washing five times 
with 2.5  ml TBS-Tween (0.5% Tween). The secondary mouse 
anti-human-IgG Dylight649 (JPT) was then incubated at room 
temperature for 1 h at a dilution of 1:5,000 in T20 blocking buffer. 
After five washings with 2.5  ml TBS-Tween, and five washes 
with double distilled de-ionized water, the slides were left to dry 
under a laminar flow hood. Samples from all timepoints from one 
individual were processed simultaneously. Slides were scanned 
on a GenePix 4000A scanner and processed using GenepixPro 
6.0 software at 650 and 532 nm to generate a Tiff image file. The 
array lay out was then added using the .gal file JPT_2758_V04.gal 
provided by JPT. Accuracy of the array alignment was controlled 
Table 2 | baseline characteristics and median follow-up by treatment 
group.
accelerated standard Total
n = 20 n = 20 n = 40
Number 20 20 40
Age (SD) 31 (25–38) 32 (22–39) 32 (23–39)
Center
 Imperial College 10 (50%) 10 (50%) 20 (50%)
 Surrey 10 (50%) 10 (50%) 20 (50%)
Gender
 Female 10 (50%) 9 (45%) 19 (47.5%)
 Male 10 (50%) 11 (55%) 21 (52.5%)
Ethnicity
 Asian 2 (10%) 0 (0%) 2 (5%)
 Mixed 0 (0%) 2 (10%) 2 (5%)
 White 18 (90%) 18 (90%) 36 (90%)
Weight (kg) 73 (63–82) 72 (67–78) 72.8 (66–78)
Routine laboratory parameters
 Hemoglobin (g/dl) 14 (13–15) 14 (13–14) 14 (13–15)
 White cell count (109/l) 7 (5.3–8.2) 6.4 (5.8–8.0) 6.5 (5.6–8.2)
 Neutrophils (109/l) 4.1 (2.9–5.1) 3.6 (3.3–5.1) 3.8 (3.0–5.1)
 Platelets (109/l) 250 (236–288) 259 (225–289) 250 (219–288)
 Lymphocytes (109/l) 1.9 (1.6–2.3) 1.9 (1.6–2.3) 1.9 (1.5–2.3)
 ALT (U/l) 20 (19–25) 19 (14–27) 21 (16–27)
 AST (U/l) 21 (18–26) 23 (18–27) 23 (18–27)
 Bilirubin (μmol/l) 10 (9–14) 11 (7–15) 10 (7–14)
 Creatinine (μmol/l) 71 (58–78) 71 (59–84) 71 (60–80)
 Glucose (mmol/l) 4.7 (4.4–5.0) 4.6 (4.5–4.9) 4.6 (4.4–4.9)
DNA/ANA antibodies
 Positive 4a (20) 0 4
 Negative 16 (80) 20 36
Follow-up (weeks, range) 43 (40–46) 45 (30–50) 44 (30–50)
aPositive only at a dilution of 1:160 which was deemed eligible.
6
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and individual features were adjusted or excluded manually when 
needed. After this QA/QC step, .gpr files were generated and 
processed further into .dat files using R-program and the R-script 
“MakeDat_V05r_stat.R” to generate one fluorescent intensity 
(FI) value for the peptide-specific IgG response from the tripli-
cates. Individual IgG responses were mapped using the R-script 
“MapAlign_BG_V11.R” after subtraction of FI values from 
baseline plasma. The array included the immunogen sequence 
CN54gp140 and nine other sequences from acute phase primary 
HIV isolates of subtypes A, C, B, CRF01_AE, and CRF02_AG 
to maximize coverage of global HIV diversity (Ahmed et al., in 
preparation).
statistical analyses
All clinical and routine laboratory data were included in the 
safety analyses. Data sets included (i) modified intention to 
treat; all participants who were randomized and received at 
least one vaccination and (ii) per protocol (PP), all participants 
who completed vaccinations with no major protocol deviations. 
The primary safety outcome was expressed as a proportion of 
participants with 95% confidence interval, and groups were 
compared using Fisher’s exact test. The primary immunologi-
cal outcome was the magnitude of serum CN54gp140-specific 
IgG 4 weeks after the final vaccination and we assumed a 100% 
response rate in the standard (reference) arm. The sample size 
was calculated on the basis of the binding antibody responses 
distributions described in the RV144 trial. In this trial, the 
reciprocal GMT of binding antibodies to subtype E gp120 was 
~1:15,000 (log10: 4.18) and for subtype B gp120 was ~1:30,000 
(log10:4.5). On the basis of previous trials, we assumed that 
everyone would respond to the CN54gp140 and that the titer of 
subtype C-specific binding antibody responses would be in the 
same range and at least 1:15,000 in the standard group and that 
a four-fold increase in the magnitude of would be immunologi-
cally relevant. This translates to an absolute difference of 0.6 on 
the log10 scale. In the absence of raw data from the Rv144 trial, 
we have assumed a standard deviation of 0.58 on the log 10 scale 
in the distribution of the antibody responses (corresponding to 
a SD of ~33,400 in titer). Assuming this variation, 20 partici-
pants per group allowed for the detection of an absolute increase 
in titer of 0.60 with 90% power and 5% alpha. Comparison of 
the groups was made using the geometric mean (GM) ratios 
of the titer with their 95% CI and equality was assumed if 
these ratios included 1. Skewed data was log transformed for 
normality and then comparisons made using parametric tests. 
Secondary outcomes were compared by the response frequency 
per group, using chi-square tests if frequencies were adequate or 
the Fisher’s exact 2-tailed test for small numbers. Comparison 
of the magnitude of T-cell ELISpot responses was made using 
the non-parametric Wilcoxon two-sample test. No corrections 
were made for multiple testing. For the flow cytometric analy-
sis, responses are described relative to each mock-stimulated 
control. Two-by-two contingency tables were generated to com-
pare the peptide stimulated versus the mock control for each 
cytokine and T-cell subset. One-sided Fisher’s exact tests were 
then applied to each table to resolve whether the percentage of 
cytokines generated following peptide stimulation was greater 
than that compared following stimulation with mock antigen. 
Bonferroni corrections were applied to account for multiple 
testing. Heatmaps summarizing ICS analyses were generated 
using SPICE version 5.1 downloaded from http://exon.niaid.
nih.gov (41).
resUlTs
Participant accrual, study Population, and 
compliance with schedule
Of 75 healthy, low-risk, HIV-negative volunteers screened 
between 19th June 2013 and 10th January 2014, 40 were enrolled; 
the reasons for the 35 who were screened out are summarized in 
Figure 1. Twenty participants were enrolled at each center, and 
baseline characteristics are summarized in Table 2. The majority 
were white, half were female and the median age was 32 years 
(IQR 23–39). All randomized participants received the first 
immunization but two in the standard group did not complete 
the immunization schedule due to adverse events. In addition, 
two participants from the standard group missed the final visit 
at weeks 40 and 1 also missed the primary immunogenicity 
endpoint visit at week 32 (Figure 1).
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Primary safety endpoints
Four (20%; 95% CI 5.73–43.66) participants in the standard 
group and one (5%; 95% CI 0.13–24.87) participant in the accel-
erated group experienced a primary safety endpoint, p = 0.342 
(two-tailed Fisher’s exact test). Two of these were ≥grade 3 
laboratory adverse events that resulted in discontinuation of vac-
cinations. Both occurred in males aged 20 years in the standard 
group. The first occurred after the first DNA; the 7-day blood 
test revealed asymptomatic transaminitis (AST 375: Grade 3, ALT 
109: Grade 2), which was confirmed 6  days later. Other blood 
tests, a viral screen, and ultrasound scan were normal. Apart 
from an episode of tonsillitis between screening and enrollment, 
treated with penicillin V, there were no other risk factors. The 
levels spontaneously returned to normal during the following 
week, but due to the temporal nature, a relationship could not be 
excluded and so vaccinations were discontinued. The second case 
occurred after administration of the second MVA-C. In between 
the immunization visit and the safety review, the participant 
reported an episode of vomiting after drinking around 12–14 
units of alcohol, and strenuous exercise. The 7-day blood test 
revealed a transaminitis (AST 530: Grade 4, ALT 184: Grade 2). 
He was not able to return for 28 days at which time both were 
within the normal range. investigations including an ultrasound 
scan and blood tests for causes of viral and non-viral hepatitides 
were normal. Although it was felt that the more likely cause of the 
transaminitis was a combination of unusually high alcohol intake 
and strenuous exercise, there was a temporal relationship with 
vaccination and so vaccinations were discontinued. There were 
five others ≥grade 3 adverse events reported by three participants 
on diary cards during the 7 days after vaccination: severe malaise 
in a female accompanied by a headache 2  days after the first 
MVA-C/CN54gp140 GLA-AF, severe malaise in a male 5  days 
after the first CN54gp140 GLA-AF, and a severe/extreme lumpy 
swelling in a female 6 days after receipt of the first MVA-C and 
then again 3 and 6 days after the second MVA-C reported by the 
same participant.
There was one serious adverse event during the study; a female 
randomized to the accelerated group was referred to hospital by 
her GP with pain and suspected appendicitis 2 days after receiving 
her first combined MVA-C and CN54gp140 vaccination. She was 
treated with paracetamol for the pain (moderate grade according 
to the toxicity table) before being discharged after an overnight 
stay when the pain had resolved. The participant continued in 
the trial and received her last immunization without a repeat of 
this problem.
Other adverse events
All of the remaining solicited local, systemic and other events 
were mild or moderate. There were 10 laboratory abnormalities 
other than those reported above, all of these were mild (5 raised 
ALT, 3 AST, 1 hyperglycaemica, and 1 bilirubin). There were dif-
ferences in reporting between the centers (125 by Surrey; 50 by 
Imperial) and by gender (119 by females; 56 by males).
immunogenicity
All analyses presented below are derived from the PP data set and 
include 20 from the accelerated group and 17 from the standard 
group unless otherwise stated (1 participant from the standard 
group who received all vaccinations did not attend the primary 
immunogenicity visit and 2 did not receive all vaccinations).
Primary immunogenicity endpoint
CN54gp140-Specific Binding Antibody
At the primary endpoint 4 weeks after the final vaccination, all 
individuals who completed the schedule made CN54gp140-
specific IgG. The GM titer and concentration of specific binding 
antibody in the accelerated group at the primary endpoint were 
6,424 (95% CI 4,391–9,396) and 10.46 µg/ml (95% CI 7.3–15.0) 
and in the standard group 6,578 (95% CI 3,927–11,020) and 
12.76  µg/ml (95% CI 8.7.0–18.75), respectively. There was no 
significant difference between the groups; as assessed by the ratio 
of the GM titer (0.98, 95 CI 0.53–1.79, p = 0.93) or concentration 
(1.46, 95% CI 0.49–4.34, p = 0.49). The response was first detected 
in both groups 4 weeks after the first MVA-C (week 20) when 
15/20 (75%) in the accelerated and 8/18 (44.4%) in the standard 
group were positive—with a greater response in the acceler-
ated group, p =  0.02. In both groups, the response increased 
significantly after each subsequent vaccination (Figure  2). In 
the accelerated group, the GMT at week 20 was 517, and this 
increased to 6,424 at week 24. In the standard group, the GM 
titer was 17 at week 20, increasing to 246 at week 24, 3,596 at week 
28, and 6,578 at week 32. In both groups, the response fell away 
again by week 40; to GMT 1,302 and 2,536 in the accelerated and 
standard groups, respectively, a difference which was significant 
(p = 0.02) (Figure 2). There was no CN54gp140-specific serum 
IgA detected at any time point.
Mucosal Antibody Responses
Of the mucosal sites sampled, CN54gp140-specific IgG was only 
detected in cervicovaginal secretions, with no specific responses 
detected in either urethral or rectal samples (Figure  3). The 
only samples included in the analyses of mucosal secretions 
were collected from women using Instead cups. There was no 
CN54gp140-specific IgG detected in samples at baseline, and at 
the primary endpoint there was no difference in the frequency of 
responders between the groups; 70% (7/10) women had detectable 
CN54gp140-specific IgG in the accelerated group as compared to 
88% (7/8) in the standard group (p = 0.59, Fisher’s exact test). The 
GM concentration of cervicovaginal CN54gp140-specific IgG was 
0.11 µg/ml (95% CI 0.01–1.28) in the accelerated group compared 
with 0.43 µg/ml (95% CI 0.05–3.7) in the standard group 4 weeks 
after the final vaccination. There was no CN54gp140-specific IgA 
detected in cervicovaginal samples.
Neutralizing Antibody Responses
Neutralizing antibody responses were detected against two Tier 
1A Env-pseudoviruses (Figure 4). At the primary endpoint 9/20 
(45%) participants in the accelerated group showed neutraliza-
tion of subtype C MW965.26 virus (closest match to CN54gp140) 
compared to 14/17 (82%) in the standard group, a difference 
which was statistically significant (p = 0.04, Fisher’s exact test) 
with higher median titer neutralization in the responders from 
the standard relative to the accelerated group (median titer of 
51 and 78, respectively). There was also a trend toward a higher 
FigUre 4 | serum neutralizing antibody responses by group. 
Neutralizing antibodies measured in serum from accelerated and standard 
groups at the primary endpoint, 4 weeks after the final vaccination: 
accelerated group, closed black circles (measured at week 24) and  
standard group, closed red circles (measured at week 32). Virus strains; 
MW965.26 (Clade C, Tier 1A), MN.3 (Clade B, Tier 1A), 00836-2.5 (Clade C, 
Tier 1B), ZM197M-PB7 (Clade C, Tier 1B), Ce1176_A3 (Clade C, Tier 2), 
Ce703010217_B6 (Clade C, Tier 2), and HIV-25710-2.43 (Clade C, Tier 2). 
Solid lines represent geometric mean titer with 95% CI. The frequency of 
responders in each group was compared using the Fishers exact test, 
*p = 0.04.
FigUre 3 | Mucosal binding cn54gp140-specific binding antibody 
responses by group. Concentrations of CN54gp140-specific cervicovaginal 
IgG responses at the primary endpoint at week 24 for accelerated (black 
circles) and week 32 for standard groups (red circles) and at week 40 for 
both. Solid lines represent geometric mean (GM) values with 95% CI. 
Comparisons were made using non-paired t-tests using GM values, and 
there were no significant differences between the groups.
FigUre 2 | serum cn54gp140-specific binding antibody responses 
by group. CN54gp140-specific serum IgG responses in accelerated (black 
closed circles) and standard groups (red closed circles). Solid lines represent 
geometric mean (GM) values with 95% CI. Comparisons made using the GM 
ratio of titers and concentration by group at the primary endpoint, and there 
were no significant differences between the groups (comparison of week 24 
for accelerated group and week 32 for standard group).
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frequency response to MN.3 (Tier 1 subtype B) in the standard 
group (10 versus 35% positive, p = 0.107). There was no neutrali-
zation detected against two Tier 1B Clade C viruses (00836-2.5, 
ZM197M-PB7) or against 2 Tier 2 clade C viruses (Ce1176_A3, 
Ce703010217_B6, HIV-25710-2.43).
Peptide Array Mapping of the Env-specific Antibody 
Response
Vaccine-induced Env-specific IgG responses to linear 15-mer 
peptides (Table 3) were mapped using a custom designed peptide 
micro array approach in subjects of accelerated group (n = 12) 
and standard group (n = 11) 4 weeks after the final vaccination. 
The immunodominant regions (IDRs) targeted and magnitude 
of region-specific responses were largely similar between the two 
groups (Figure 5). IDRs were exlusively located within gp120 with 
little recognition of gp41. Basic characteristics of IDR-specific 
IgG responses including the representative peptide sequence 
targeted and mean fluorescence intensity within each group are 
summarized in Figure 5. Within gp120, four consecutive peptides 
covering the tip of the V3 region (indicated as peak 5, aa300 to 
320 (HxB2 reference strain) were targeted by >90% of vaccinees 
with a high mean fluorescence intensity (MFI) (referring to the 
highest measured response, if multiple peptides covered for this 
region) of above 50,000 units in both groups. Other IDRs were 
located in the C1 region (peak 1; HxB2 aa position 104–124 and 
peak 2; HxB_aa117–136) with maximum MFIs of 43,000 and 
25,000 in standard and accelerated groups, respectively; in the 
FigUre 5 | specificity of systemic binding antibody responses to env by group. Frequency of recognition of linear overlapping peptides spanning the HIV 
envelope in plasma samples from the accelerated (n = 12, upper panel) and the standard groups (n = 11, lower panel). The y axis shows the proportion of 
individuals recognizing the specified peptides and the x axis denotes the distribution of linear peptides along the envelope with relevant regions of interest 
highlighted.
Table 3 | antigenic peaks of recognition in env.
Peak number hXb2 env region representative sequence MFi standard MFi accelerated
1 104 C1a MHEDIISLWDQSLKP 34650 19507
1 107 C1a DVISLWDQSLKPCVK 43478 25183
1 109 C1a ISLWDQSLKPCVKLT 41274 21634
2 119 C1b/V1 SVKLTPLSVTLNSTD 11993 x
2 121 C1b/V1 KLTPLCVTLNCTNAK 29195 x
3 200 C2 AITQACPKVTFDPIP 30593 25445
4 245 C2 VQCTHGIKPVVSTQL 33780 36173
4 249 C2 HGIKPVVSTQLLLNG 15699 20643
5 300 V3 GNNTRKSIRIGPGQT 44475 40678
5 301 V3 NNTRKSIHIGPGQAF 60570 59711
5 304 V3 RKSINIGPGRAFYAT 59915 59186
5 305 V3 TSIRIGPGQTFYATG 59589 56526
6 429 C4 EVGKAMYAPPIKGQI x 15762
6 433 C4 AMYAPPIKGQIKCLS x 19922
7 473 C5 GDMRNNWRSELYKYK 34577 22160
7 475 C5 MKDNWRSELYKYKVV 37522 22782
8 491 C5 IKPLGVAPTTTKRRV 35026 35758
Summary of HxB location, Envelope region, representative peptide sequences, and mean fluorescence intensity (MFI) of the most frequently recognized antigenic regions in Env 
displayed in Figure 5 and the MFI of each peak from standard (n = 11) and accelerated (n = 12) groups.
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C2 region (peak 3; HxB_aa200–215 and peak 4; HxB_aa245–264) 
with MFIs between 25,000 and 35,000; and in the C4 (peak 6 
HxB2_aa429–457) and C5 regions (peak 7, HxB2_aa473–490 
and peak 8, HxB2_aa491–504) were targeted with MFIs between 
20,000 and 38,000. All these IDRs were recognized by 70% of 
vaccines in at least one group. There was no significant differ-
ences between the groups in terms of the number of epitopes 
recognized, the magnitude of individual responses or the sum of 
fluorescence intensity values for all peptide variants recognized 
that were included in the array (p = 0.21).
FigUre 6 | T-cell elispot responses by group over time to vaccine encoded peptide pools. Distribution of IFNγ ELISpot responses (background 
subtracted; spot forming units per million PBMCs) prior to and following vaccine candidate administration for six HIV-1 peptide pools; CN54 1/2, Env 1 (a) and 2 
(b), ZM65 Gag (c), Nef (D), 5′ Pol (e), and 3′ Pol (F). Boxes represent the interquartile ranges, whiskers extend to the 5th and 95th percentiles and the green bar is 
the median. Red circles represent positive responses, black circles are negative responses. Accelerated group: open boxes, n = 20, Standard group: orange boxes, 
n = 18. Dashed line is the ELISpot assay positive response value (38 SFU/million PBMCs).
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T-Cell ELISpot Responses
There were no IFNγ ELISpot responses at baseline and 8 weeks 
after the third DNA vaccination (week 16) responses were seen 
in a minority of individuals to Env peptide pools (20.5% overall). 
At the primary endpoint, there was no difference in either the 
frequency or magnitude of ELISpot responses between groups; 
85 and 82.4% responded to any pool in the accelerated and 
standard groups, respectively, at the primary endpoint (p = 1.00) 
with overall GM values of 111 and 147 SFC/106 PBMCs (p = 0.44) 
Figure  6. All responding individuals recognized one or both 
Env peptide pools (75.0 and 76.5% recognizing Env pool 1 and 
65.0 and 64.7% recognizing Env pool 2 for the accelerated and 
standard groups, respectively, p values >0.99) and the magnitude 
of these responses was similar between groups [medians 70–189 
SFC/106 PBMCs for the two Env pools (p =  0.09–0.32)]. Gag 
peptide-specific responses were relatively modest and detected 
in only 25% of the accelerated and 23.5% of the standard group 
(p = 1.00) with similar magnitude (median 58 and 86 SFC/106 
PBMCs, p = 0.28). There were no responses to the 5′ Pol pool in 
either group and none of the accelerated group and 17.6% of the 
standard group responded to the 3′ Pol pool (p = 0.09, median 
43 SFC/106 PBMCs). None of the accelerated group and 5.9% of 
standard group responded to Nef peptides (p = 0.46, 1 response 
of 179 of SFC/106 PBMCs in the standard group). At this time 
point, the mean number of peptide pools recognized (out of a 
total possible of 6) for each subject was similar between groups; 
1.65 and 1.88 for the accelerated and standard groups respectively 
(median of 2 for both groups, p = 0.63). In terms of magnitude, 
responses to Env pools peaked 4 weeks after the second MVA-C/
CN54gp140 (median 111 SFC/106 PBMCs) in the accelerated 
group and 4 weeks after the first MVA-C in the standard group 
(median 213 SFC/106 PBMCs). While the great majority of 
responses in both groups recognized Env or Env plus Gag pep-
tides, recognition of ENV in combination with Nef or 3′Pol or of 
Gag peptides was only seen in the standard group—accounting 
for approximately 17% of all responses (data not shown). In the 
FigUre 7 | heatmaps showing the frequency of different cytokine responses by T-cell subset over time by group. Overall frequency of different 
combinations of three cytokines (IFNγ, IL2, and TNFα) produced by CD4 (a) and CD8 (b) T-cells responses to combinations of P5/6 Env peptide pools by week. 
The highest frequency (% of total) is shown in red and the lowest in blue (scale depends on maximal response). Due to the low frequency of responses, no formal 
statistical comparisons were made between the groups.
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accelerated group, responses to Env and Gag peptides dropped 
between weeks 24 and 40 (p = 0.04, 0.02) whereas in the standard 
group there was no significant change (p = 0.4, 0.65). At week 
40, the responses to Env and Gag peptide pools was of greater 
magnitude in the standard than the accelerated group (p = 0.03, 
0.02, and 0.091, respectively) and more frequent to Env peptides, 
with 71% responding to both Env peptide pools in the former 
compared to 37 and 47% in the latter (p =  0.09 for responses 
to Env 1 pool) and this was also true of responses to Gag pep-
tide pools with 30% responding in the standard and 5% in the 
 accelerated group.
Intracellular Cytokine Responses
Overall, intracellular cytokine responses were modest and 
results are therefore descriptive. The majority of responses were 
polyfunctional and focused toward Env rather than Gag peptide 
pools. Response rates to any antigen at any post-baseline visit, 
for both CD4 and CD8 populations, were higher in the standard 
than the accelerated group, 50 versus 30% respectively for CD4+, 
and 33.3 versus 10% for CD8+ lymphocytes, but these differences 
were not statistically significant (data not shown). CD4 and CD8 
responses to all antigens were predominantly polyfunctional, 
with IFNγ being the dominant cytokine (Figure 7). The standard 
group tended toward higher CD8 responses (IFNγ+TNFα+) 
while both groups had comparable CD4 responses (the majority 
being IL2+IFNγ+). In the standard group, responses seemed to 
peak at week 24 and wane at week 32 in CD4 lymphocytes but 
were more persistent in some CD8 lymphocytes (data not shown).
DiscUssiOn
We have compared two vaccination regimens using identical 
DNA-C, MVA-C, and GLA adjuvanted CN54gp140 with the aim 
of assessing the safety and immunogenicity of a shortened regi-
men in which the MVA and adjuvanted protein were combined. 
We expected strong Env-specific CD4+ T-cells after DNA and 
MVA and Env-specific binding antibodies in everyone after 
adjuvanted gp140 and the study was powered to detect a four-fold 
difference in the magnitude of this response between groups. As 
expected, 100% individuals made strong CN54gp140-specific 
antibody irrespective of regimen, but combining the vaccines 
had no detectable impact on the magnitude or specificity of 
the antibody response as assessed by the recognition of linear 
peptides. This pattern was characterized by strong recognition 
of V3 with notably little recognition within gp41—in spite of 
its presence in the DNA and gp140 vaccines. The immunogens 
also induced recognition of linear epitopes within C2 and C4, 
but their significance, if any, is unknown. Despite these binding 
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antibody responses, neutralizing antibody responses were disap-
pointing and only seen to Tier 1A pseudoviruses, similar to our 
previous experiences using this adjuvanted protein (27, 28). 
Interestingly, however, the frequency and titer of the responses 
was inferior when vaccines were combined to two Tier 1A pseu-
doviruses. There was no difference in the overall frequency or 
specificity of T-cell ELISpot responses which were seen in >80% 
individuals irrespective of group and tended to be CD4+ and 
specific for Env peptide pools. While the great majority of IFNγ 
ELISpot responses were seen to Env peptide pools in both groups, 
recognition of Gag, Nef and Pol peptides was less frequent in the 
accelerated group suggesting that combining the vaccines might 
have led to further polarization of immune responses. Cytokine 
responses were relatively modest, but also less frequent or less 
polyfunctional in both CD4+ and CD8+ compartments when the 
MVA and CN54gp140 were combined. There was no significant 
impact of combining the vaccines upon tolerability. Although 
two participants experienced events that resulted in discontinu-
ation of immunizations, these followed different immunogens 
(DNA-C, MVA-C) and there were alternative explanations for the 
asymptomatic elevation in transaminases in each case. The great 
majority of adverse events were mild in line with our previous 
experience using the same adjuvanted protein in different settings 
(27, 28).
Even though we controlled for variables such as site and 
gender, the study has limitations; overall statistical power was 
compromised by the fact that we did not have 40 in the final 
analyses as planned. Nevertheless, there was clear evidence that 
combining MVA and gp140 led to attenuation of certain T-cell 
and B-cell immune responses. Both regimens were shorter overall 
than used in previous studies using similar homologous (22–24) 
or heterologous DNA and MVA (26, 42) and it remains possible 
that the time between DNA prime and MVA boost (8  weeks) 
might have been too short to allow for the optimal maturation of 
immune responses. The use of a common and semi-quantitative 
assay for the measurement of CN54gp140-specific IgG antibody 
allows for direct comparison across our different trials. The 
median CN54gp140- specific binding antibody response seen 
here (12.8 µg/ml) exceeds that seen in the Mucovac 2 trial (UK 
HVC_001) after three doses of CN54gp140/GLA-AF IM in the 
absence of DNA priming (4.2  µg/ml) (27), but is lower than 
seen in the TaMoVac 01 trial (UK HVC_00 2) after boosting 
twice with GLA-AF adjuvanted CN54gp140 30–71  weeks after 
priming with DNA and MVA (17.8 µg/ml) (28). This supports 
the value of DNA/MVA priming and suggests that the long 
gap between prime and boost could be important. Sallusto and 
colleagues propose a minimum gap of 12 weeks and note that if 
boosting is too frequent, responding cells might be preferentially 
driven to terminal differentiation resulting in attenuation of 
immunity (43).
Our decision to use immunogens expressing matched sub-
type C inserts was driven by our commitment to a vaccine for 
use in Sub-Saharan Africa as well a belief that this approach 
would ellicit high titer binding antibodies and so favor func-
tional/neutralizing antibodies. In addition to the logistical 
advantages offered by fewer vaccinations, we were interested 
in combining the pox and protein in light of the results of 
the RV144 trial which included combined canarypox and 
alum adjuvanted gp120 and was the first ever trial of an HIV 
vaccine to show (modest) efficacy. In UK HVC_003 overall, 
immunogenicity was somewhat disappointing and it remains 
possible that the combined MVA and adjuvanted gp140 protein 
may have overwhelmed the pool of antigen-specific/innate 
immune cells, as offered as one explanation of the attenuation 
in responses sometimes seen when certain pediatric vaccines 
are combined (44, 45) and which might be particularly associ-
ated with MVA at it has been shown to be highly immunogenic 
and to preferentially deplete antigen presenting cells (46–48). 
Immunogenicity may have been further compromised in the 
accelerated group as a result antigenic competition (even 
though the vaccines were administered into opposite arms) as 
has been suggested to occur in response to response to certain 
combinations of conjugated vaccines (49) and observed more 
recently in an HIV vaccine trial in South Africa (25). The choice 
of adjuvant was partly practical as we had access to GLA-AF 
through the UK HVC and had already used it with the same 
gp140 protein (27, 28). In our hands, the GLA-AF (MPLA) 
adjuvant has previously been shown to be potent for antibodies 
at equivalent (3 ×  100  µg) and lower (3 ×  20  µg) doses (27) 
(in the absence of DNA/MVA), and we had every reason to 
suspect that priming would further enhance these responses. 
We expected the immunogens to be at least as immunogenic as 
those used in RV144 in both groups and, based on our previous 
experiences with DNA and MVA, predicted that they would be 
more potent for T-cells.
In light of these findings, we remain cautious about the 
accelerated regimen, and feel that the combined MVA-C and 
adjuvanted GLA-AF warrants further evaluation in a regimen 
with a longer gap between priming and boost. We believe this 
trial provides further support for exploring the clinical efficacy 
of a priming regimen including DNA, with at gap of least 
12  weeks prior to boosting. The precise contribution of adju-
vanted protein (if any) is yet to be defined. While Churchyard 
and colleagues reported no clear benefit of DNA priming on 
Env-specific antibody responses, T-cell responses appeared 
augmented by the priming although overall immunogenicity in 
the trial was lower than seen previously using the same vaccines 
in a different population (25). In light of our previous experi-
ence with a variety of immunogens, we remain committed to 
the inclusion of DNA as we believe balanced immune responses 
highly desirable. We await data from a direct comparison of the 
specificity of antibody responses from trials using different het-
erologous prime boost regimens (including RV144 and Tamovac 
01) with this one to inform our selection of immunogens to take 
forward. Non-neutralizing IgG antibody responses targeting V2 
have been shown to correlate with a reduced risk of HIV using 
a variety of different approaches, although we did not see much 
response to linear peptides within this region (9, 50, 51) suggest-
ing perhaps that they are associated with the subtype E gp120 
protein. We did however see strong recognition of the V3 loop in 
both groups and this has been described as characteristic of the 
responses seen during natural infection (27) and also in other 
vaccine trials including RV144-when the response correlated 
with reduced risk of HIV acquisition in a subset of individuals 
13
Joseph et al. Comparison of Two Vaccine Regimens
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 149
(51). In conclusion, the vaccines were potent irrespective of 
regimen, but immunogenicity was lower than anticipated, and 
we cannot exclude the possibility that this was due to the rela-
tively short regimens. Our data suggest that combining MVA 
and CN54gp140/GLA-AF in this relatively short regimen had 
no significant impact on safety and also no impact on the mag-
nitude of CN54gp140-specific systemic antibody responses and 
the strategy may have attenuated immunogenicity as reported 
previously (25).
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